Neoplasm Recurrence, Local

"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.

Descriptor ID	D009364
MeSH Number(s)	C04.697.655 C23.550.727.655
Concept/Terms	Neoplasm Recurrence, Local Neoplasm Recurrence, Local Local Neoplasm Recurrences Locoregional Neoplasm Recurrence Recurrences, Local Neoplasm Neoplasm Recurrences, Local Recurrence, Local Neoplasm Recurrence, Locoregional Neoplasm Local Neoplasm Recurrence Neoplasm Recurrence, Locoregional Locoregional Neoplasm Recurrences Neoplasm Recurrences, Locoregional Recurrences, Locoregional Neoplasm

Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".

Diseases [C]
Neoplasms [C04]
Neoplastic Processes [C04.697]
Neoplasm Recurrence, Local [C04.697.655]
Pathological Conditions, Signs and Symptoms [C23]
Pathologic Processes [C23.550]
Neoplastic Processes [C23.550.727]
Neoplasm Recurrence, Local [C23.550.727.655]

Below are MeSH descriptors whose meaning is related to "Neoplasm Recurrence, Local".

Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.

Bar chart showing 297 publications over 30 distinct years, with a maximum of 28 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1997	0	1	1
1998	0	2	2
2000	0	1	1
2001	0	1	1
2002	1	2	3
2003	0	1	1
2004	2	3	5
2005	1	2	3
2006	2	3	5
2007	2	3	5
2008	3	3	6
2009	4	3	7
2010	3	8	11
2011	5	9	14
2012	6	7	13
2013	13	1	14
2014	11	7	18
2015	9	3	12
2016	9	2	11
2017	7	7	14
2018	8	8	16
2019	4	10	14
2020	4	15	19
2021	7	21	28
2022	1	25	26
2023	0	18	18
2024	9	7	16
2025	4	6	10
2026	2	0	2

Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.

Han F, Lv X, Zhou YJ, He Q, Guo Y, Xiang YQ, Shu XL, Pan SM, Qu SH, Zhang P, Jiang Y, Xu MJ, Lei KJ, Qu S, Wang XH, Jin YS, Zhao B, Dai R, Wang FH, Xu RH. Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial. Med. 2026 Apr 10; 7(4):101029.

View in: PubMed
Masanam MK, Bellon JR, Leone JP, Mittendorf EA, King TA, Kantor O. Breast-Conserving Therapy for Multiple Ipsilateral Breast Cancer After Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2026 Apr; 33(4):3355-3363.

View in: PubMed
Boysen M, Lai SH, Byers S, Widmar M, Loria A, Russell T, Abelson JS, Fleming FJ, Monson JR, Vogel JD. Rectal Cancer Watch-and-Wait Management of Patients With Tumors Within Versus Beyond the Reach of Digital Rectal Examination. Ann Surg Oncol. 2026 Apr; 33(4):2856-2864.

View in: PubMed
He SQ, Huang Y, Zhao ZY, Wen SQ, Lv SH, Wang L, Bei WX, Xiang YQ, Liu GY. Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study. Br J Cancer. 2026 Feb; 134(4):598-607.

View in: PubMed
Zewde MG, Peyser DK, Yu AT, Bonaccorso AM, Moshier EL, Alavi K, Goldstone RN, Marks JH, Maykel JA, McLemore EC, Sands DR, Steele SR, Wexner SD, Whiteford MH, Sylla P. Impact of Obesity on Postoperative Outcomes in Transanal Total Mesorectal Excision for Rectal Cancer. Dis Colon Rectum. 2026 Apr 01; 69(4):553-564.

View in: PubMed
Herrera-Caceres JO, Wettstein M, Matin SF, Labbate C, Potretzke A, Rodriguez R, Singla N, Pallauf M, Huang W, Nagpal S, Kleinmann N, Shvero A, Small A, Green B, Linehan J, Choe J, Shah O, Rai A, Kaimakliotis H, Tachibana I, Canes D, Perecman A, Raman JD. Outcomes of endoscopic management for upper tract urothelial carcinoma: A multi-center international cohort analysis. Urol Oncol. 2025 Dec; 43(12):697.e1-697.e9.

View in: PubMed
Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM. Long-Term (=5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 Sep; 43(25):2766-2771.

View in: PubMed
Freitas AJA, Causin RL, Calfa S, Santana IVV, Balie M, Hirai W, Laus AC, Araujo HS, Hidalgo Filho CM, de Oliveira Bombarda F, da Silva VD, Evangelista AF, de P?dua Souza C, Reis RM, Marques MMC. Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes. Breast Cancer Res Treat. 2025 Jul; 212(2):237-250.

View in: PubMed
Cucinella G, Schivardi G, Zhou XC, AlHilli MM, Wallace S, Covens A, Wohlmuth C, Baiocchi G, Tokgozoglu N, Raspagliesi F, Buda A, Zanagnolo V, Zapardiel I, Jagasia N, Giuntoli R, Glickman A, Peiretti M, Lanner M, Chacon E, Di Guilmi J, Pereira A, Laas E, Fishman A, Nitschmann CC, Kurnit K, Moriarty K, Joehlin-Price A, Lees B, De Brot L, Taskiran C, Bogani G, Landoni F, Chiva L, Grassi T, Bianchi T, Multinu F, De Vitis LA, Hernandez-Gutierrez A, Mastroyannis S, Ghoniem K, Palmieri E, Chiantera V, Maryam S, Fought AJ, McGree ME, Mariani A, Glaser G. Prognostic value of isolated tumor cells in sentinel lymph nodes in intermediate-risk endometrial cancer: results from an international, multi-institutional study. Int J Gynecol Cancer. 2025 Jul; 35(7):101906.

View in: PubMed
Valabrega G, Powell MA, Hietanen S, Miller EM, Novak Z, Holloway R, Denschlag D, Myers T, Thijs AM, Pennington KP, Gilbert L, Fleming E, Zub O, Landrum LM, Ataseven B, Gogoi R, Podzielinski I, Cloven N, Monk BJ, Sharma S, Herzog TJ, Stuckey A, Pothuri B, Secord AA, Chase D, Vincent V, Meyers O, Garside J, Mirza MR, Black D. Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial. Int J Gynecol Cancer. 2025 Jun; 35(6):101852.

View in: PubMed

People

Explore

Similar Concepts

Top Journals